German company BioNTech is betting big on its new cancer drug, and for good reason. In Phase 2 trials, BNT111 showed a marked improvement in patients with advanced melanoma as compared to traditional treatments. BNT111 was paired with Regeneron’s Libtayo, a PD-1 inhibitor. Trials continue as the company explores various secondary endpoints, but so far the news is excellent for BioNTech.
From COVID To Cancer
If the name BioNTech seems familiar, it’s because they partnered with Pfizer to create one of the most widely available mRNA vaccines for COVID-19. It was first to market in the United States, receiving an emergency authorization just 9 months after the pandemic reached our shores. Both Pfizer and BioNTech got a massive boost as a result, but four years on, interest in COVID vaccines has waned.
The company has long believed in the power of mRNA to revolutionize medicine, though, as its cancer moonshot proves. It’s set an ambitious goal of having 10 cancer drugs approved by 2030. Whether the company will reach that target is anyone’s guess, but the recent results demonstrate that mRNA treatments can be successful, at least for certain cancers.
What The Analysts Are Saying
Analysts tend to agree that BioNTech is a buy, with the usual caveats. Cancer will affect nearly 40% of people sometime in their lives, and treating it remains incredibly challenging. Even if only a small portion of BioNTech’s cancer drugs ever make it to market, there is a tremendous potential upside for investors. But of course, nothing is ever guaranteed, particularly with new healthcare technologies. There’s always a risk that a particular drug may not work as expected in late-stage trails or even once it’s released to the public. BioNTech is mitigating that risk by maintaining several drugs in trials at once, but investors should still consider the risk versus reward before going all-in.
Neither Lisa Fritscher nor Stocks.News has positions in this company.
Did you find this insightful?
Bad
Just Okay
Amazing
Disclaimer: Information provided is for informational purposes only, not investment advice. We do not recommend buying or selling stocks. Stock price discussions are based on publicly available data. Readers should conduct their own research or consult a financial advisor before investing. Owners of this site have current positions in stocks mentioned thru out the site, Please Read Full Disclaimer for details Here https://app.stocks.news/page/disclaimer
Contributing Writer
Lisa Fritscher has been a contributing writer for App.Stock.News since 2024. Lisa has been interested in investing since winning The Stock Market Game in high school. In more than a decade as a professional writer, she has written consumer-facing financial information and advice articles for a wide variety of publications. She has a Bachelor of Arts in Psychology from the University of South Flori...